Intracellular fatty acid levels differentially impact target silencing by FDA-approved siRNA drugs
Sherouk M Tawfik1, Le Tra Giang Nguyen1, Jing Jin1
1Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.
Abstract:
With seven approved and many more anticipated over the next decade, small interfering RNA (siRNA) therapeutics have emerged as an innovative class of nucleic acid-based drugs, offering potential treatments for both rare and common diseases. A substantial portion of the patient population affected by these diseases may also present with obesity and metabolic-associated fatty liver disease (MAFLD), conditions characterized by excessive accumulation of hepatic free fatty acids (FFAs). However, the impact of intracellular FFA levels on siRNA drug efficacy has not been fully determined. In this study, hepatic HepG2 and HepaRG cells were treated with varying concentrations of oleic and palmitic acids to simulate a microcellular environment with elevated FFA levels. Efficacy in the reduction of targets at both the mRNA and protein levels was determined for three selected Food and Drug Administration (FDA)-approved siRNA drugs, patisiran, vutrisiran, and inclisiran. Our findings demonstrate strong evidence that elevated intracellular FFA levels significantly alter the efficacy of the FDA-approved siRNA drugs, impacting both mRNA and protein target reduction and highlighting a previously underexplored factor which could impact clinical outcomes. Understanding the impact on siRNA efficacy is critical for optimizing the therapeutic potential of siRNA-based treatments for patients with FFA diseases, such as obesity and MAFLD.
Insights
Elevated free fatty acids (FFAs) in liver cells significantly impact the effectiveness of small interfering RNA (siRNA) drugs. This finding is crucial for optimizing siRNA therapeutics for patients with metabolic diseases like obesity and MAFLD.
Area of Science:
- Biochemistry
- Pharmacology
- Hepatology
Background:
- Small interfering RNA (siRNA) therapeutics represent a promising drug class for various diseases.
- Obesity and metabolic-associated fatty liver disease (MAFLD) are prevalent conditions often co-occurring with diseases treated by siRNA.
- The influence of intracellular free fatty acid (FFA) levels on siRNA drug performance remains largely unknown.
Purpose of the Study:
- To investigate the impact of elevated intracellular FFA levels on the efficacy of FDA-approved siRNA drugs.
- To determine how altered FFA concentrations affect target gene and protein reduction by siRNA therapeutics in hepatic cells.
Main Methods:
- Hepatic cell lines (HepG2 and HepaRG) were treated with varying concentrations of oleic and palmitic acids to mimic high FFA conditions.
- The efficacy of three FDA-approved siRNA drugs (patisiran, vutrisiran, inclisiran) was assessed by measuring mRNA and protein target reduction.
Main Results:
- Elevated intracellular FFA levels were found to significantly alter the efficacy of the studied siRNA drugs.
- The reduction of both mRNA and protein targets by siRNA was demonstrably impacted by increased FFA concentrations.
- This suggests FFA levels are a critical factor influencing siRNA therapeutic outcomes.
Conclusions:
- Intracellular FFA levels represent a significant, previously underexplored factor affecting siRNA drug efficacy.
- Understanding this interaction is vital for enhancing the therapeutic potential of siRNA treatments in patients with metabolic conditions.
- Further research is warranted to optimize siRNA drug delivery and efficacy in the context of elevated FFAs.
More Related Videos
13:40Live Cell Calcium Imaging Combined with siRNA Mediated Gene Silencing Identifies Ca2+ Leak Channels in the ER Membrane and their Regulatory Mechanisms
Published on: July 7, 2011
10:29Applying Fluorescence Resonance Energy Transfer FRET to Examine Effector Translocation Efficiency by Coxiella burnetii during siRNA Silencing
Published on: July 6, 2016
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi
01:22MicroRNAs
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...